Therapeutic Targeting of TP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1α with Echinomycin

TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically targeted. Here we showed HIF-1α target genes are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yin, Liu, Yan, Bailey, Christopher, Zhang, Huixia, He, Miao, Sun, Duxin, Zhang, Peng, Parkin, Brian, Baer, Maria R., Zheng, Pan, Malek, Sami N., Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291851/
https://www.ncbi.nlm.nih.gov/pubmed/32060420
http://dx.doi.org/10.1038/s41388-020-1201-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291851/
https://www.ncbi.nlm.nih.gov/pubmed/32060420
http://dx.doi.org/10.1038/s41388-020-1201-z

Ejemplares similares